To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation.

Not Applicable

• Conditions: Multiple myeloma

• Registration Number: JPRN-UMIN000007838
• Lead Sponsor: Kanshinetsu Multiple Myeloma Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-27
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

Not provided

Exclusion Criteria

1. Non-secretory MM and plasmacell leukemia. 2. Patients HIV-HBs-and HCV-positive 3. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4. Patients with a history of active malignancy during the past 5 years. 5. Patients with psychiatric disorders such as schizophrenia etc. 6. Pregnant women, pre-menopausal women, and lactating women. 7. History of hypersensitivity to mannitol or boron. 8. Patient was suspected pneumonia(Interstitial pneumonia). Consult a respiratory specialist if necessary 9. Those who are considered as inappropriate to register by attending physicians.

Study & Design

• Study Type: Interventional
• Study Design: Not specified